3P Biotechnologies, Inc.

Prospect, KY 40059

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $1.24MM
First Award Date 07/16/12
Most Recent Award Date 09/26/17

Key Personnel

Last Name Name Awards Contact
Spencer Wendy A Spencer 3
Gupta Ramesh Chander Gupta 7

4 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 09/26/17 - 08/31/18

Technical Abstract As with many chemotherapeutic drugs, taxanes exhibit poor oral bioavailability; hence, they are administered intravenously (i.v.). This regimen results in significant toxicities, due to both the high drug dose and vehicle (Cremophore ELR) used. Attempts made to develop an oral chemotherapeutic, using liposomes and polymeric n...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-13-235
Budget: 09/05/14 - 02/28/15

DESCRIPTION (provided by applicant): More people in the U.S. (160,340 per year) die of lung cancer than of prostate, breast, and colon cancer combined. The most common type of lung cancer, non-small-cell lung cancer (NSCLC), accounts for 75% of all lung cancers. Regrettably, 85% of all patients diagnosed with NSCLC eventually die of the disease ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 07/01/13 - 12/31/13

DESCRIPTION (provided by applicant): Cervical cancer, which is caused by HPV infection, is characterized by the progressive formation of dysplastic lesions, known as cervical intraepithelial neoplasia (CIN). Although vaccinations for the prevention of cervical cancer have been developed, the current vaccine has a high cost, targets only two-thi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 07/16/12 - 06/30/13

DESCRIPTION (provided by applicant): Cervical cancer, which is caused by HPV infection, is characterized by the progressive formation of dysplastic lesions, known as cervical intraepithelial neoplasia (CIN). Although vaccinations for the prevention of cervical cancer have been developed, the current vaccine has a high cost, targets only two-thi...